These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 16342922)

  • 1. Creative and innovative statistics in clinical research and development.
    Maurer W
    Methods Inf Med; 2005; 44(4):551-60. PubMed ID: 16342922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idle thoughts of a 'well-calibrated' Bayesian in clinical drug development.
    Grieve AP
    Pharm Stat; 2016; 15(2):96-108. PubMed ID: 26799060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statistical innovations in the medical device world sparked by the FDA.
    Campbell G; Yue LQ
    J Biopharm Stat; 2016; 26(1):3-16. PubMed ID: 26372890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian statistics in medical devices: innovation sparked by the FDA.
    Campbell G
    J Biopharm Stat; 2011 Sep; 21(5):871-87. PubMed ID: 21830920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innovative approaches in drug development.
    Chang M; Kenley S; Bull J; Chiu YY; Wang W; Wakeford C; McCarthy K
    J Biopharm Stat; 2007; 17(5):775-89. PubMed ID: 17885865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dermatology clinical trials and drug development.
    Ehrenberger HE; Joshi TG
    Dermatol Nurs; 2003 Oct; 15(5):428-34. PubMed ID: 14619320
    [No Abstract]   [Full Text] [Related]  

  • 7. Perspectives on the use of adaptive designs in clinical trials. Part II. Panel discussion.
    Benda N; Brannath W; Bretz F; Burger HU; Friede T; Maurer W; Wang SJ
    J Biopharm Stat; 2010 Nov; 20(6):1098-112. PubMed ID: 21058105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The identification of benefit in medical intervention: an overview and suggestions for process.
    Stang PE; Pham SV; Kinchen K; Raff SB; Mussen F; Gondek K
    Am J Ther; 2008; 15(5):495-503. PubMed ID: 18806527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and analysis of bridging studies with prior probabilities on the null and alternative hypotheses.
    Zeng D; Pan Z; Lin DY
    Biometrics; 2020 Mar; 76(1):224-234. PubMed ID: 31724739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The draft FDA guideline on non-inferiority clinical trials: a critical review from European pharmaceutical industry statisticians.
    Huitfeldt B; Hummel J;
    Pharm Stat; 2011; 10(5):414-9. PubMed ID: 21932294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA draft guidance on adaptive design clinical trials: Pfizer's perspective.
    Chuang-Stein C; Beltangady M
    J Biopharm Stat; 2010 Nov; 20(6):1143-9. PubMed ID: 21058110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials.
    Marchetti S; Schellens JH
    Br J Cancer; 2007 Sep; 97(5):577-81. PubMed ID: 17726450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innovative approaches to clinical development and trial design.
    Orloff JJ; Stanski D
    Ann Ist Super Sanita; 2011; 47(1):8-13. PubMed ID: 21430331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing the value delivered by the statistician throughout drug discovery and development: putting statistical science into regulated pharmaceutical innovation.
    Enas GG; Andersen JS
    Stat Med; 2001 Sep 15-30; 20(17-18):2697-708. PubMed ID: 11523077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006.
    Wang Y; Bhattaram AV; Jadhav PR; Lesko LJ; Madabushi R; Powell JR; Qiu W; Sun H; Yim DS; Zheng JJ; Gobburu JV
    J Clin Pharmacol; 2008 Feb; 48(2):146-56. PubMed ID: 18199891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statistical approaches for conducting network meta-analysis in drug development.
    Jones B; Roger J; Lane PW; Lawton A; Fletcher C; Cappelleri JC; Tate H; Moneuse P;
    Pharm Stat; 2011; 10(6):523-31. PubMed ID: 22213533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New paradigm for drug developments--from emerging market statistical perspective.
    Quan H; Chen X; Zhang J; Zhao PL
    Contemp Clin Trials; 2013 Nov; 36(2):697-703. PubMed ID: 23810938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adaptive design of confirmatory trials: Advances and challenges.
    Lai TL; Lavori PW; Tsang KW
    Contemp Clin Trials; 2015 Nov; 45(Pt A):93-102. PubMed ID: 26079372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moving in Parallel Toward a Modern Modeling Epistemology: Bayes Factors and Frequentist Modeling Methods.
    Rodgers JL
    Multivariate Behav Res; 2016; 51(1):30-4. PubMed ID: 26881955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statistical considerations associated with a comprehensive regulatory framework to address the unmet need for new antibacterial therapies.
    Dane A; Wetherington JD
    Pharm Stat; 2014; 13(4):222-8. PubMed ID: 24931419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.